Follow The Filings

STRO Sutro Biopharma Inc.

Health Care, filed as SUTRO BIOPHARMA INC (COM SHS), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 exit

In 2026 Q2 James Silverman sold out of Sutro Biopharma.

Who owns STRO

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management exited 2026 Q2 Last 2026 Q1 0.63% Exit −0.63% 190,671 $4.8M History

0 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by STRO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All STRO insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. David Pauling Chief Admin. Ofcr. & GC
    Buy
    $9,993 12,504 shares at $0.8000 +21% to stake
    Traded Oct 15, 2025 Filed Oct 16, 2025
    ↗
  2. Hans-Peter Gerber Chief Scientific Officer
    Buy
    $14K 17,000 shares at $0.8000 +31% to stake
    Traded Oct 15, 2025 Filed Oct 16, 2025
    ↗
  3. Jane Chung CEO
    Buy
    $10K 12,500 shares at $0.8000 +11% to stake
    Traded Oct 15, 2025 Filed Oct 16, 2025
    ↗
  4. Gregory K. Chow CFO
    Buy
    $16K 19,750 shares at $0.8100 New stake
    Traded Oct 15, 2025 Filed Oct 16, 2025
    ↗
  5. Connie Matsui Director
    Buy
    $40K 50,000 shares at $0.8000 New stake
    Traded Oct 15, 2025 Filed Oct 16, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 13 option exercises and 10 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
424B3 Filing Doc
8-K 1.02,2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
424B5 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $153.73M $62.04M $102.48M
Net income -$106.79M -$227.46M -$191.09M
Net margin * -69.5% -366.6% -186.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $421.54M $343.31M $150.93M
Total non-current assets * $49.19M $43.9M $22.9M
Total assets $470.74M $387.21M $173.83M
Total current liabilities $93.75M $131.89M $75.13M
Total non-current liabilities * $227.34M $210.71M $231.15M
Total equity $149.65M $44.6M -$132.45M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$111.62M -$191.54M -$177.23M
Cash from investing -$3.92M $218.51M $45.01M
Cash from financing $137.55M $94.05M $0.044M
Net change in cash $22.01M $121.02M -$132.17M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.